{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:15Z","timestamp":1789609095654,"version":"build-2803163510"},"reference-count":36,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious adverse syndrome occurring 5 to 30 days after adenoviral vector COVID-19 vaccination. Therefore, a practical evaluation of clinical assessments and laboratory testing for VITT is needed to prevent significant adverse outcomes as the global use of adenoviral vector vaccines continues. We received the clinical information and blood samples of 156 patients in Canada with a suspected diagnosis of VITT between April and July 2021. The performance characteristics of various diagnostic laboratory tests were evaluated against the platelet factor 4 (PF4)-14C-serotonin release assay (SRA) including a commercial anti-PF4\/heparin immunoglobulin G (IgG)\/IgA\/IgM enzyme immunoassay (EIA, PF4 Enhanced; Immucor), in-house IgG-specific anti-PF4 and anti-PF4\/heparin-EIAs, the standard SRA, and the PF4\/heparin-SRA. Of those, 43 (27.6%) had serologically confirmed VITT-positive based on a positive PF4-SRA result and 113 (72.4%) were VITT-negative. The commercial anti-PF4\/heparin EIA, the in-house anti-PF4-EIA, and anti-PF4\/heparin-EIA were positive for all 43 VITT-confirmed samples (100% sensitivity) with a few false-positive results (mean specificity, 95.6%). These immunoassays had specificities of 95.6% (95% confidence interval [CI], 90.0-98.6), 96.5% (95% CI, 91.2-99.0), and 97.4% (95% CI, 92.4-99.5), respectively. Functional tests, including the standard SRA and PF4\/heparin-SRA, had high specificities (100%), but poor sensitivities for VITT (16.7% [95% CI, 7.0-31.4]; and 46.2% [95% CI, 26.6-66.6], respectively). These findings suggest EIA assays that can directly detect antibodies to PF4 or PF4\/heparin have excellent performance characteristics and may be useful as a diagnostic test if the F4-SRA is unavailable.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007766","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T22:25:00Z","timestamp":1653431100000},"page":"4228-4235","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8040-8473","authenticated-orcid":false,"given":"Anna-Lise","family":"Bissola","sequence":"first","affiliation":[{"name":"1Department of Medicine, Michael G. DeGroote School of Medicine,"},{"name":"2Department of Biochemistry and Biomedical Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7149-2781","authenticated-orcid":false,"given":"Mercy","family":"Daka","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Michael G. DeGroote School of Medicine,"},{"name":"2Department of Biochemistry and Biomedical Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-8853","authenticated-orcid":false,"given":"Donald M.","family":"Arnold","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Michael G. DeGroote School of Medicine,"},{"name":"3McMaster Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Michael G. DeGroote School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Moore","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Michael G. DeGroote School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Clare","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Michael G. DeGroote School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Ivetic","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Michael G. DeGroote School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9418-2383","authenticated-orcid":false,"given":"John G.","family":"Kelton","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Michael G. DeGroote School of Medicine,"},{"name":"3McMaster Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5695-4343","authenticated-orcid":false,"given":"Ishac","family":"Nazy","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Michael G. DeGroote School of Medicine,"},{"name":"3McMaster Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"issue":"22","key":"2022072016271683600_B1","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med."},{"issue":"22","key":"2022072016271683600_B2","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med."},{"issue":"23","key":"2022072016271683600_B3","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med."},{"key":"2022072016271683600_B4","article-title":"Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine"},{"issue":"8","key":"2022072016271683600_B5","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N Engl J Med."},{"key":"2022072016271683600_B6","article-title":"Coronavirus vaccine - weekly summary of Yellow Card reporting"},{"issue":"4","key":"2022072016271683600_B7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID-19vaccination-United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann Intern Med."},{"issue":"18","key":"2022072016271683600_B8","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med."},{"issue":"7","key":"2022072016271683600_B9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.amjmed.2008.03.012","article-title":"A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia","volume":"121","author":"Warkentin","year":"2008","journal-title":"Am J Med."},{"issue":"8","key":"2022072016271683600_B10","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.V98.8.2442","article-title":"Heparin-induced thrombocytopenia\/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA","volume":"98","author":"Reilly","year":"2001","journal-title":"Blood."},{"issue":"1","key":"2022072016271683600_B11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","article-title":"Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia","volume":"68","author":"Amiral","year":"1992","journal-title":"Thromb Haemost."},{"issue":"20","key":"2022072016271683600_B12","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1182\/blood-2008-10-186064","article-title":"Studies of the immune response in heparin-induced thrombocytopenia","volume":"113","author":"Warkentin","year":"2009","journal-title":"Blood."},{"issue":"2","key":"2022072016271683600_B13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jth.14369","article-title":"Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia","volume":"17","author":"Huynh","year":"2019","journal-title":"J Thromb Haemost."},{"issue":"7873","key":"2022072016271683600_B14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature."},{"issue":"6","key":"2022072016271683600_B15","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.15341","article-title":"Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on Platelet Immunology","volume":"19","author":"Nazy","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"2","key":"2022072016271683600_B16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.seminhematol.2022.03.003","article-title":"Laboratory testing for VITT antibodies","volume":"59","author":"Warkentin","year":"2022","journal-title":"Semin Hematol."},{"key":"2022072016271683600_B17","author":"Vaccines for COVID-19"},{"issue":"11","key":"2022072016271683600_B18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamaneurol.2021.3619","article-title":"Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia","volume":"78","author":"S\u00e1nchez van Kammen","year":"2021","journal-title":"JAMA Neurol."},{"issue":"7","key":"2022072016271683600_B19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ajh.24025","article-title":"Pitfalls in the diagnosis of heparin-induced thrombocytopenia: a 6-year experience from a reference laboratory","volume":"90","author":"Nazi","year":"2015","journal-title":"Am J Hematol."},{"issue":"10","key":"2022072016271683600_B20","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jth.13066","article-title":"Distinguishing between anti-platelet factor 4\/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia","volume":"13","author":"Nazi","year":"2015","journal-title":"J Thromb Haemost."},{"issue":"8","key":"2022072016271683600_B21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1538-7836.2008.03025.x","article-title":"Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays","volume":"6","author":"Warkentin","year":"2008","journal-title":"J Thromb Haemost."},{"key":"2022072016271683600_B22","doi-asserted-by":"crossref","first-page":"100270","DOI":"10.1016\/j.lanepe.2021.100270","article-title":"Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany","volume":"12","author":"Thiele","year":"2022","journal-title":"Lancet Reg Health Eur."},{"issue":"4","key":"2022072016271683600_B23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/jth.15233","article-title":"A comparative study of platelet factor 4-enhanced platelet activation assays for the diagnosis of heparin-induced thrombocytopenia","volume":"19","author":"Rubino","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"5","key":"2022072016271683600_B24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.14955","article-title":"Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies","volume":"179","author":"Vayne","year":"2017","journal-title":"Br J Haematol."},{"issue":"1","key":"2022072016271683600_B25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V67.1.27.27","article-title":"A diagnostic test for heparin-induced thrombocytopenia","volume":"67","author":"Sheridan","year":"1986","journal-title":"Blood."},{"key":"2022072016271683600_B26","doi-asserted-by":"crossref","article-title":"Risk of vaccine-induced thrombotic thrombocytopenia (VITT) following the AstraZeneca\/COVISHIELD adenovirus vector COVID-19 vaccines","author":"Chan","DOI":"10.47326\/ocsat.2021.02.28.1.0"},{"key":"2022072016271683600_B27","first-page":"1","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus vector COVID-19 vaccination","author":"Pai","year":"2021"},{"issue":"22","key":"2022072016271683600_B28","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMc2112974","article-title":"Vaccine-induced thrombocytopenia with severe headache","volume":"385","author":"Salih","year":"2021","journal-title":"N Engl J Med."},{"key":"2022072016271683600_B29","article-title":"Interim case definition of thrombosis with thrombocytopenia syndrome (TTS)","author":"Chen"},{"key":"2022072016271683600_B30","doi-asserted-by":"crossref","first-page":"100274","DOI":"10.1016\/j.lanepe.2021.100274","article-title":"Most cases of thrombosis and thrombocytopenia syndrome (TTS) post ChAdOx-1 nCov-19 are vaccine-induced immune thrombotic thrombocytopenia (VITT)","volume":"12","author":"Makris","year":"2021","journal-title":"Lancet Reg Health Eur."},{"issue":"4","key":"2022072016271683600_B31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2106383","article-title":"PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia","volume":"385","author":"Vayne","year":"2021","journal-title":"N Engl J Med."},{"issue":"9","key":"2022072016271683600_B32","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/jth.15423","article-title":"Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: results from a UK National External Quality Assessment Scheme exercise April 2021","volume":"19","author":"Reilly-Stitt","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"5","key":"2022072016271683600_B33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.26488","article-title":"Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies","volume":"97","author":"Kanack","year":"2022","journal-title":"Am J Hematol."},{"issue":"8","key":"2022072016271683600_B34","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jth.15362","article-title":"Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination","volume":"19","author":"Platton","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"3","key":"2022072016271683600_B35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pathol.2021.10.008","article-title":"Laboratory testing for platelet factor 4 antibodies: differential utility for diagnosis\/exclusion of heparin induced thrombocytopenia versus suspected vaccine induced thrombotic thrombocytopenia","volume":"54","author":"Favaloro","year":"2022","journal-title":"Pathology."},{"issue":"12","key":"2022072016271683600_B36","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1055\/a-1535-9002","article-title":"PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison","volume":"121","author":"Sachs","year":"2021","journal-title":"Thromb Haemost."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4228\/1909778\/advancesadv2022007766.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/14\/4228\/1909778\/advancesadv2022007766.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T16:27:55Z","timestamp":1658334475000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/14\/4228\/485335\/The-clinical-and-laboratory-diagnosis-of-vaccine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007766","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]}}}